USA VC Funds

Pear VC (formerly Pejman Mar Ventures) is one of Silicon Valley's most respected pre-seed and seed specialist venture firms, founded in August 2013 by Pejman Nozad and Mar Hershenson and rebranded from Pejman Mar to Pear VC in August 2016 with the launch of its $75 million Fund II. Headquartered in Menlo Park, California, the firm leads rounds and has scaled its fund platform from a $50 million first fund to $160 million (Fund III) and an oversubscribed $432 million Fund IV closed in 2023, bringing cumulative capital raised to roughly $700 million. The 25-person team includes Founding Managing Partners Pejman Nozad and Mar Hershenson and Partner Kathleen Estreich. Pear operates an explicit three-stage framework covering pre-seed through Series A and has built distinctive sourcing programs including PearX, Pear Pre-Seed Ready, and an Emerging Managers in Residence program launched in September 2024. Across 263 investments Pear has seeded three public companies: DoorDash, Guardant Health, and Senti Biosciences. Additional billion-dollar breakouts from the portfolio include Gusto, Branch, Aurora Solar, and Vanta. In 2025 the firm made 34 new investments, with seven more in the first quarter of 2026. The firm has recorded 27 portfolio exits to date, including BioAge Labs and Voyage AI. The most recent liquidity event was the exit of Breakout Audio in May 2025. Pear VC combines high-frequency seed deployment with deep programmatic engagement, running accelerator-style programs that give the firm proprietary access to emerging founders before they reach the market. The result is a sourcing advantage built over a decade of community investment in Stanford, MIT, and the broader Silicon Valley founder ecosystem.

Pebblebed is an early-stage venture capital firm founded in 2022, based in San Francisco, California. The firm focuses on investing in technology companies that demonstrate profound technical insight and have the potential to build long-term competitive advantages. Pebblebed targets investments in companies that create significant value through innovation, aiming to support startups that are capable of developing strong market positions and enduring customer relationships. Pebblebed is particularly interested in businesses that can establish deep end-user stickiness, build strong brand loyalty, or create high switching costs for customers, thereby ensuring sustainable growth and market leadership. The firm’s investment strategy is characterized by its emphasis on deep technical knowledge, leveraging the expertise of its partners who have extensive backgrounds in engineering and technology. The firm has made several investments across various sectors, including AI, computing infrastructure, and other tech-driven industries. Pebblebed’s approach is to provide more than just capital; it aims to be a strategic partner to its portfolio companies, offering guidance and resources to help them scale and succeed in competitive markets.

Pegasus Tech Ventures, based in Silicon Valley, is a global venture capital firm managing over $2 billion in assets. Founded in 2011, Pegasus offers a unique Venture Capital-as-a-Service (VCaaS) model, partnering with large corporations to invest in emerging tech startups. This involves vetting investment opportunities, managing investments, and connecting startups to a network of over 30 international corporate partners to accelerate growth. Notable investments include high-profile companies such as SpaceX, Twitter, Airbnb, SoFi, DoorDash, and 23andMe. Pegasus' diverse portfolio spans sectors like consumer electronics, automotive, healthcare, AI, and fintech, reflecting its broad investment strategy. Recently, Pegasus launched a $100 million fund with Denka Company Limited, focusing on ICT, energy, healthcare, and sustainable living. This fund aims to invest in startups across the US, Europe, Israel, and Asia, enhancing Denka's growth and innovation efforts. Additionally, Pegasus founded and sponsors the Startup World Cup, one of the largest startup competitions globally, with a $1 million investment prize. This competition supports regional innovation ecosystems worldwide and connects them to Silicon Valley. Led by founder and CEO Anis Uzzaman, Pegasus leverages its extensive global network and deep tech expertise to drive corporate innovation and help emerging tech companies achieve industry leadership.

Pelion Venture Partners, based in Salt Lake City, Utah, is a prominent venture capital firm that has been active since 1986. The firm focuses on early-stage investments in technology sectors, including enterprise software, digital media, SaaS, and cloud services. Pelion has made over 300 investments, with notable exits such as Cloudflare, Domo, and Venafi. Their investment strategy involves supporting startups with innovative solutions and strong growth potential. Pelion typically invests in seed and Series A rounds, providing the necessary capital and strategic support to help companies scale. Recent investments include companies like Jump and Cartwheel​.

Perceptive Xontogeny Venture Fund (PXV) is the early-stage life-sciences venture capital platform of New York-based Perceptive Advisors, operated in strategic partnership with Boston-based accelerator and operating company Xontogeny. Perceptive Advisors launched its venture strategy with Perceptive Xontogeny Venture Fund I in 2018, an oversubscribed $210 million vehicle backed by endowments, foundations, family offices, and institutional investors. Fund II closed in May 2021 at $515 million, bringing the combined platform to more than $700 million dedicated to financing early-stage private life-sciences companies. The Investment Committee is anchored by Joe Edelman (CEO of Perceptive Advisors), Adam Stone (CIO of Perceptive Advisors), and Chris Garabedian (Portfolio Manager and Chairman and CEO of Xontogeny), alongside operating partners Fred Callori and Ben Askew, PhD. The platform leads rounds and invests typical checks of $10 million to $20 million, targeting 8 to 10 concentrated positions per fund across biotechnology, medtech, digital health, and healthcare tools and services. Across its 27 investments, PXV has backed Landos Biopharma (the first Xontogeny company, acquired by AbbVie in May 2024 as the platform's headline exit), Lexeo Therapeutics (which entered a partnership with venBio Partners in June 2025 providing up to $40 million for novel cardiac RNA therapeutics), and other early-stage therapeutics companies. Xontogeny's operating role distinguishes PXV from traditional life-sciences funds: the platform provides deep operational support from the pre-company stage through clinical and commercial scale-up, allowing the investment team to co-build companies alongside founders rather than simply writing checks and attending board meetings.

Pereg Ventures is an early-stage cross-border venture capital firm founded in 2012 by Managing Partners Itzhak Fisher and Ziv Ben-Barouch and headquartered in Midtown Manhattan, with deep operational roots in Israel. Venture Partner Mark Leiter complements the founding team, which collectively brings more than three decades of investment and startup operating experience across more than 100 prior investments. The firm invests in disruptive B2B data-driven ventures that accelerate consumer-facing enterprises, with a focus on retail technology, e-commerce, digital marketing, and consumer-behavior analytics. Pereg's core thesis leans on its dual geographic footprint: sourcing raw technological innovation from Israel while providing US market access, distribution, and go-to-market expertise to portfolio companies. The firm leads rounds in seed through Series B stages. Pereg Ventures Fund I closed in February 2015 with anchor support from Nielsen, which provided a significant LP commitment, alongside Tata. The portfolio consists of 18 companies including one unicorn: Bringg, which reached unicorn status in 2021 four years after Pereg's first investment. Additional portfolio companies include Onclusive, RetailNext, Nutrino, CB4, Engage3, Discuss.io, Crosswise, Syte, ChannelEyes, Cielo24, OurCart, Quaero, and Staq. The firm has produced one IPO and six acquisitions. The most recent exit was RetailNext in January 2025, and the most recent new investment was a December 2024 controlling-stake acquisition of AI apparel commerce platform Syte, co-led by Pereg with Magma VC, MizMaa, and Stardom Ventures. Pereg's Israel-US bridge model gives it early access to enterprise data and analytics technology coming out of Israel's deep talent pool in intelligence and cybersecurity, which it then connects to some of the world's largest retail and consumer brands in the United States.

Peregrine Ventures is Israel's first dedicated healthcare-focused venture capital fund, founded in 2001 in Or Yehuda by serial entrepreneur brothers Eyal Lifschitz (Co-Founder and General Managing Partner) and Boaz Lifschitz (Co-Founder and General Partner), who previously co-founded biomedical device companies Visioncare Ophthalmic Technologies and BioControl in the 1990s. The firm today manages approximately $600 million in assets across a multi-fund platform that pairs early-stage venture investing with Peregrine Growth, a $300 million late-stage life-sciences fund launched in November 2020, plus earlier funds including a $115 million med-tech vehicle. Partners Tamir Tal, Lior Shahory, David Eldar, and Shiran Tehila Mashiah complement the founding team. A distinctive feature of the platform is its embedded synergy with the Incentive Incubator, giving portfolio companies deep operating support from the pre-company stage through clinical and commercial scale-up. Peregrine leads rounds and has made approximately 172 investments into around 75 active and realized portfolio companies, with one unicorn, one IPO, and 16 acquisitions to date. Notable outcomes include Insightec, Quicklizard, and Eledon. Startup Nation Central named Peregrine Israel's most active healthtech investor for 2024, based on 15 strategic health-tech deals. The investment scope covers life sciences broadly: healthcare, digital health, medical devices, therapeutic devices, pharma, biotechnology, and medical software. Recent investments include Lutris Pharma ($30 million, January 2025) and Aluma Healthcare in September 2025. Peregrine's 25-year track record in Israeli healthcare and its deeply integrated incubator model create a continuum from scientific concept to clinical validation that few other investors can offer. By maintaining active involvement at every stage from incubation through growth equity, the firm builds durable portfolio relationships that extend well beyond a standard investment horizon.

Perle Ventures is a Sydney-based growth-stage technology venture capital firm founded in 2013 by Co-Founder and Chairman Shayne Smyth, the entrepreneur who founded and later divested Cover-More, Australia's largest integrated travel insurance and medical assistance provider, and Co-Founder and Managing Director Michael An, who brings more than 20 years of experience as a founder, investor, board member, and adviser across technology, education, telecommunications, and financial services. The firm operates as a compact three-person platform and concentrates on seed and growth-stage investments in Australian technology companies, with selective exposure to Singapore and the United States. Sector focus spans enterprise applications, fintech, high tech, retail, marketplace, and vertical SaaS. Perle's portfolio numbers roughly 25 investments including one unicorn, Dapper Labs, and realized outcomes of seven IPOs and three acquisitions. Notable portfolio names include Coinbase, Dapper Labs, FiscalNote, TradeGecko, Simple, Spriggy, Academy Xi, and Wattwatchers. The most recent documented investment is Dapper Labs in March 2022, with no publicly disclosed new deployments since, suggesting the firm is operating in portfolio-management mode. Perle Ventures benefits from its founders' complementary backgrounds: Smyth's experience scaling and exiting a major Australian consumer business provides commercial pattern recognition, while An's multi-decade technology investment career provides deal-origination breadth. Together they offer founders access to corporate networks, capital market relationships, and cross-border connectivity spanning Australia, Singapore, and the United States, making Perle a value-added partner for technology companies scaling from the Asia-Pacific region into global markets.

Perot Jain is a Dallas-based early-stage venture capital firm co-founded by Ross Perot Jr. and Anurag Jain in 2014. The firm primarily focuses on investing in innovative and disruptive startups within the healthcare, mobility, business services, and tech-enabled B2B sectors. Notable investments include companies like Access Healthcare, specializing in healthcare IT solutions, and Worlds, which creates AI-generated models for business process optimization. Other significant portfolio companies are Spacee, which offers virtual store walkthroughs, and Booster, a mobile fuel delivery service. Perot Jain typically invests up to $500,000 in seed and Series A rounds, aiming to support scalable businesses located in the United States. The firm leverages its extensive network and operational expertise to provide more than just capital, offering strategic guidance and resources to help startups achieve transformational growth. The team at Perot Jain includes a mix of founders, executives, and industry experts who work closely with entrepreneurs to drive innovation and impact. The firm has made over 70 investments and maintains a strong presence in the North Texas startup ecosystem, contributing to the region's growth as a national center for technology and innovation.

Perspectiv Ventures is a Singapore-based early-stage venture capital firm founded in 2015 and led by Managing Partner and Chief Strategist GheeHoe Cheng. The firm provides seed and early-stage funding to technology-driven ventures across three core thematic verticals: healthtech and medtech, fintech and blockchain, and AI and robotics, operating primarily across Southeast Asia with additional connectivity to the United States. Beyond capital, Perspectiv offers strategic guidance on growth, scaling, and governance in the digital business and smart-services landscape, typically participating in follow-on rounds as startups mature. The team of five includes one Partner, two Venture Partners, and one Principal, providing geographical and sectoral coverage across Singapore and the US. The firm's internal decision framework is branded 'MTTM' covering Market, Talent, Technology, and Momentum, giving its evaluation process a structured lens that goes beyond product-market fit to assess the full commercial trajectory of each investment. Perspectiv has made 13 investments across healthtech, fintech, AI, blockchain, hardware and robotics, and SaaS. Named portfolio companies include Aniday, a Southeast Asian HR and recruitment SaaS platform, and Wellcare, a clinics and outpatient-services operator. The most recent publicly documented investment is Aniday in September 2019, with no new investments publicly recorded in 2024 or 2025. Perspectiv Ventures occupies a niche as an early specialist in the Southeast Asian digital economy, having established its position in Singapore before the current wave of larger regional and international funds entered the market. GheeHoe Cheng's background in both strategic advisory and early-stage investing gives the firm a practitioner's perspective on what it takes to commercialize technology across Southeast Asia's fragmented regulatory and consumer landscape.

Peterson Ventures is a seed-stage venture capital firm that helps entrepreneurs build successful businesses from the ground up. Headquartered in Utah with an additional office in the Bay Area, Peterson Ventures focuses on SaaS, digital commerce, fintech, and healthtech sectors. The firm typically invests $250K to $1M in early-stage startups, aiming to bridge the gap between angel investors and traditional venture capital. Founded in 2008 as part of the Peterson Partners platform, Peterson Ventures has invested in over 200 companies, including notable names like Allbirds, Ethos, Lucid Software, and HireVue. The firm recently raised $140 million for its fourth fund and its first opportunity fund, allowing continued investment in their best-performing portfolio companies as they scale. The firm is led by Managing Director Ben Capell, with a team of experienced partners and associates who bring diverse backgrounds in entrepreneurship, investment banking, and corporate strategy. Peterson Ventures is known for its founder-first approach, providing not just capital but also strategic guidance and support to help startups overcome challenges and achieve growth.

Petri Bio is a biotechnology company focused on developing next-generation therapeutics derived from gut microbes. The company leverages the vast genetic information within the microbiome to discover and develop novel treatments for challenging diseases such as inflammatory bowel disease (IBD) and fatty liver disease. These diseases often have limited effective treatments, making Petri Bio's work particularly impactful. Founded by Shu Li, a Ph.D. in plant biology, and Joseph Schinaman, a biomedical researcher, Petri Bio is committed to using microbial compounds to create new medicines. Their approach involves mining microbial genomes for peptides with therapeutic potential, which they believe could lead to breakthroughs in treating various conditions that are currently underserved by existing pharmaceutical solutions. Petri Bio has also been involved in the development of treatments related to COVID-19, using their platform to identify compounds that could potentially neutralize the virus. Their work has garnered attention and interest from major pharmaceutical companies, and they continue to expand their pipeline to include other critical areas of healthcare.

Pfizer Venture Investments (Pfizer Ventures) is the corporate venture capital arm of Pfizer Inc., established in 2004 and headquartered in New York. The platform carries a $900 million total capital commitment, including a $600 million top-up announced in Q4 2021, and backs private companies at all stages of development with a strong bias toward early-stage therapeutics and platform technologies. Investment priorities mirror Pfizer's therapeutic areas: inflammation and immunology, internal medicine, oncology, and neuroscience, extending into platform technologies, diagnostics, drug delivery, pharmaceutical services, and healthcare IT. Roughly 25 percent of available capital, approximately $150 million, is explicitly earmarked for early-stage neuroscience investments. Across approximately 200 investments, Pfizer Ventures has built a concentrated neuroscience portfolio including Aquinnah, Autifony, Cortexyme, MindImmune, Mission Therapeutics, and Neuronetics. The platform leads rounds and invests globally, though deployments skew toward US-based companies. Recent notable investments include Curve Therapeutics (GBP 40.5 million Series A, led in February 2024), Enara Bio ($32.5 million Series B co-led with M Ventures in October 2024), Enlaza Therapeutics ($100 million Series A syndicate in September 2024), OTR Therapeutics ($100 million Series A for a Chinese biotech in June 2025), and Crossbow Therapeutics in March 2026 as the most recent disclosed investment. Pfizer Ventures serves as a strategic window on early-stage innovation across life sciences globally. Portfolio companies benefit not only from capital but also from Pfizer's regulatory expertise, clinical development networks, and therapeutic-area know-how, creating pathways to partnership, licensing, and acquisition that financial-only investors cannot offer.

Phenomen Ventures (Phenomen VC) is a mid-to-late-stage global venture capital firm founded in 2012 and based primarily in London, United Kingdom. The firm describes itself as investing in 'internet and tech phenomenons' — category-leading, fastest-growing companies across the United States, Europe, and Israel. Phenomen focuses on information technology, SaaS, and consumer internet, predominantly at Series A and Series B stages, with particular historical emphasis on Germany-based startups. The firm operates with a lean team of three partners and has more than $300 million in committed capital across 22 investments, with portfolio companies reaching customers in 35 countries. The portfolio carries an enviable track record with two major European consumer-tech IPOs: HelloFresh (listed on Euronext in November 2017 at a $1.91 billion market cap) and Delivery Hero (listed on the Frankfurt Stock Exchange at a $5.01 billion market cap). Four portfolio companies have been acquired in total, including FREE NOW, which was acquired by Lyft for $199 million in April 2025. Other disclosed portfolio companies include Arbox (business and productivity software, most recent investment in September 2025), Constru, Foodpanda, and LightYX. Phenomen Ventures applies a concentrated, conviction-driven approach to identifying category-defining companies at the Series A and B junctures where growth trajectories become apparent but valuations remain constructive. The firm's track record in consumer internet and food technology, combined with its pan-European perspective and US and Israeli deal connectivity, positions it as a specialist partner for founders seeking a globally networked investor with demonstrated success in scaling internet businesses to IPO.

Philips Ventures is the venture capital arm of Royal Philips, focusing on early- to growth-stage investments in healthcare technology startups that align with Philips’ mission to improve patient outcomes, reduce healthcare costs, and transform the healthcare experience. Established in 1998 and based in Amsterdam, Philips Ventures invests globally, supporting companies that develop digital health solutions, medical devices, and health technology services. The fund is business-agnostic but emphasizes sectors like digital software, AI-driven health solutions, and technology-enabled services. Philips Ventures provides not just capital but also strategic support, offering startups access to Philips' extensive clinical and regulatory expertise, global market insights, and deep relationships within the healthcare industry. Their investment strategy includes leading or co-leading rounds, with initial investments typically ranging from $2 million to $5 million, and they actively syndicate deals to collaborate with other investors. Philips Ventures also fosters partnerships between their portfolio companies and Philips' various business units, helping startups scale and navigate the complex healthcare landscape. This approach has led to investments in companies like Elucid, Validic, and MIVI Neuroscience, all of which are pushing the boundaries of healthcare innovation.

Philips Venture Capital Fund (Philips Ventures) is the corporate venture capital arm of Royal Philips, the Dutch multinational health technology company. Founded in 1998 and based in Amsterdam at the Amstelplein 2 Breitner Tower, Philips Ventures deploys strategic capital into early- to growth-stage health technology startups whose innovations complement Philips' global healthcare portfolio and digital transformation agenda. The fund is led by Managing Partner Nate Harrington and operates with a lean two-person team at the fund level. As a corporate and strategic investor, Philips Ventures leverages Philips' deep domain expertise, global commercial footprint, and research and development capabilities to add value to portfolio companies beyond capital alone. Investment activity focuses on Series A and Series B rounds in digital software and technology-enabled healthcare services, predominantly in US-based startups with global activity. The fund has made 22 investments across healthtech, AI, and medical devices and hardware. Notable portfolio companies include PreciseDx (diagnostic equipment, latest investment as part of a Series B-II round in June 2025 as the firm's most recent disclosed deployment), Endovascular Engineering, and R3 Vascular. Recorded exits include Carevive Systems in June 2024 and ALung, acquired by LivaNova in May 2022. The firm currently states it is not investing in development-stage or pre-clinical businesses. Philips Ventures focuses on innovations that can reduce costs, improve clinical outcomes, and transform the patient and clinician experience in ways that align with Philips' strategic roadmap. Portfolio companies benefit from the potential to pilot solutions within Philips' customer network, access the firm's technical talent, and leverage its global healthcare commercial relationships across hospitals, imaging centers, and health systems worldwide.

Phoenix Venture Partners (PVP) is a Silicon Valley-based venture capital firm founded in 2009 and headquartered in San Mateo, California, with satellite offices in Singapore and Cambridge, Massachusetts. The firm specializes in taking transformative hard-technology innovations in advanced materials, novel devices, innovative manufacturing processes, and state-of-the-art tools from proof-of-concept to commercialization. Founder and Managing General Partner John Chen leads a team of seven, including five partners. PVP's core thesis targets what the firm calls Convergent Tech: the intersection of advanced materials, biology, and hardware with advanced computation and AI, investing in early-to-revenue-stage companies tackling pain points in computing, electronics, transportation, energy, industrial applications, and life sciences. Typical checks range from $100,000 to $7.5 million, and the firm leads Series A rounds. Over its 19-year history, PVP has made 85 investments, averaging two new investments per year in the last decade, and has recorded 3 IPOs and 17 acquisitions. Notable portfolio outcomes include AbSci (PVP led the 2016 Series A; AbSci listed on NASDAQ in July 2021 at a $1.45 billion market cap), NBD Nanotechnologies, and COTSWORKS (exited in July 2025). Recent investments include UbiQD (Series B-II in February 2026 as the most recent disclosed investment), Qolab (superconducting quantum computing), ORAN Development, and Nanofiber Quantum Technologies. Phoenix Venture Partners provides founders with hands-on support in business development, IP strategy, recruitment, and exit planning, leveraging a global network of strategic partners spanning manufacturing, government, and enterprise markets. Its specialist positioning in hard tech and advanced materials makes it one of the few firms capable of leading early institutional rounds in deep-science companies that require both technical diligence and long commercialization timelines.

PHX Ventures is a seed-stage venture capital firm based in Tempe, Arizona, founded in 2018 by software entrepreneur Gregg Scoresby, also the founder of CampusLogic, to fill a structural gap in the Arizona software ecosystem: institutional-quality seed capital for high-growth local B2B SaaS companies. Operating Partner Chris Chumley, previously Chief Operating Officer at CampusLogic, complements Scoresby's operating background. PHX Ventures is Arizona's most active software investor, investing exclusively in B2B SaaS and leading or co-leading seed rounds of $1 million to $5 million. The firm's sweet-spot target is Arizona-based B2B SaaS companies with annual recurring revenue of $100,000 to $1 million that are on a credible path to institutional growth. PHX Ventures' oversubscribed Fund II closed at $25.4 million in 2023, backed by successful Arizona software entrepreneurs, executives, advisers, and principals from top-tier US growth-equity firms. The firm also operates a venture studio that builds SaaS companies in-house and has a goal of investing in 30 B2B software companies by 2030. As of 2025, PHX has made 16 or more investments with 12 Arizona-headquartered companies. Portfolio companies span enterprise applications, vertical SaaS, fintech, healthtech, and AI. Named portfolio companies include Rivia Health, Better Agency, Nurture Boss, RTA/Fleet360 (Series A in April 2025), and Fluint (most recent disclosed investment in August 2025). PHX Ventures combines founder-operator credibility with proximity to the Arizona tech ecosystem, bringing a practical understanding of software business-building rather than purely financial expertise. Its fund-plus-studio model gives it access to both market-sourced deals and proprietary company creation, expanding the pipeline relative to a traditional seed fund.

USA, the UK, and Russia. The firm specializes in early-stage investments, focusing on high-tech sectors such as AI, mobility, energy, biotech, and space technology. Phystech Ventures supports startups that leverage scientific advancements to create disruptive solutions and transform industries. The firm's portfolio includes investments in various industries like the internet of things, connected platforms, automotive, education technology, cybersecurity, sensors, robotics, and energy tech. Notable investments include companies such as Osome, H2Drone, Geosteering Technologies, and Coda Devices​​. Phystech Ventures is driven by a team of experienced professionals, including Daniel Shaposhnikov, who leads AI/ML, energy, and mobility verticals, and Ivan Protopopov, who oversees life sciences and space tech investments​.

Picus Capital, founded in 2015 and headquartered in Munich, Germany, is an early-stage venture capital firm with a long-term investment philosophy. The firm focuses on technology-driven sectors such as financial services, HR, energy & climate, healthcare, logistics & mobility, real estate & construction, crypto & web3, deep tech, and e-commerce. Picus Capital has made significant investments in companies like Ledge, Spot My Energy, Cove Living, Poolit, and Alasco, among others. Their portfolio spans across 20+ countries with a diverse range of startups that are innovating in their respective fields. The firm's unique approach emphasizes close partnerships with their portfolio companies, assisting them with strategic decisions and operational challenges. With offices in Munich, London, New York, Beijing, and other key locations, Picus Capital is well-positioned to support global growth and expansion. The firm is led by co-founders Robin Godenrath, Alexander Samwer, and Jeremias Heinrich, who bring extensive experience and a strong entrepreneurial mindset to the table. Their team is dedicated to helping daring technology companies build successful, global enterprises that challenge the status quo and shape the future​

Pillar VC is a venture capital firm based in Boston, Massachusetts, specializing in early-stage investments, particularly in pre-seed and seed rounds. Founded in 2016, the firm focuses on supporting founders from the very beginning, often before formal incorporation, and invests in various sectors including AI/ML, biotech, consumer, enterprise, fintech, and crypto/web3. Pillar VC manages multiple funds, including the recent $192 million raised for Pillar III and Pillar Select. This allows them to continue backing companies with significant potential to become foundational pillars of their industries. Their investment strategy includes leading seed rounds with investments ranging from $2 million to $6 million and making pre-seed investments between $50,000 and $500,000. The firm is distinguished by its commitment to buying common stock to align closely with the founders' interests. Pillar VC also provides robust support through a dedicated platform team that assists with talent acquisition, expert connections, pitch polishing, and investor introductions. This approach has helped foster successful companies like Algorand, Desktop Metal, and PillPack​.

Pilot House Ventures is a Boston, Massachusetts-based early-stage venture capital firm founded in 2001 and headquartered at The Pilot House, Lewis Wharf. The firm historically focused on promising early-stage technology companies in enterprise software, network infrastructure, internet, and communications. Managing Director Benjamin A. Gomez and Partner Eric P. Krauss led the three-person team. Pilot House typically entered at the Series A financing stage with initial checks of $2 million to $4 million, giving preference to New England-based companies it could support in person. The firm managed four funds, including Pilot House Ventures II LP. Across its history, Pilot House made 72 investments and delivered one IPO and 12 acquisitions. Notable exits include Stoke, BigBand Networks, and Mazu Networks. The firm built a strong regional reputation as an active Series A partner for Boston-area enterprise technology and networking startups. The most recent tracked portfolio exit was Qualtre in January 2016, and the firm's most recent disclosed new investments date to 2021, indicating that Pilot House is effectively inactive and no longer deploying capital into new deals. Pilot House Ventures played a meaningful role in the Boston technology ecosystem during the early 2000s and 2010s, providing regionally focused, hands-on venture support to enterprise software and communications companies at a time when New England VC was less crowded than today. Its operational history of 72 investments and more than 30 total exits reflects a consistent strategy of backing capital-efficient enterprise technology companies with clear paths to acquisition by larger platform vendors.

Ping An Ventures is the corporate venture capital arm of Ping An Insurance (Group) Company of China, one of China's largest insurance and financial services conglomerates. Founded in 2012 with RMB 1 billion (~$150 million) of seed capital from Ping An Insurance, the firm is headquartered in Pudong, Shanghai and holds the distinction of being the first VC fund launched out of China's financial industry. Ping An Ventures invests across fintech, healthcare, consumer, and technology verticals — spanning domestic and overseas opportunities — with a focus on middle-to-late growth rounds, pre-IPO, and PIPE transactions that align with Ping An's own digital transformation roadmap. The firm has made approximately 160 investments across its history, with check sizes typically ranging from $3 million to $50 million. To extend its global reach, Ping An Ventures launched the Hong Kong-based Global Voyager fund at $1 billion to source healthcare and fintech assets in the United States, Israel, and Singapore, and has targeted up to $1.3 billion across two additional healthcare-focused growth-stage funds. Notable portfolio companies include Didi Chuxing, Meituan-Dianping, Oscar Health, Payoneer, Taulia, Hycor Biomedical, Fabric Genomics, and Tmunity Therapeutics. Recent exits include eToro and Fabric Genomics, acquired by GeneDx for $51 million in April 2025. Ping An Ventures operates with a lean team of eight investment professionals and maintains a disciplined approach to portfolio construction, concentrating on companies where Ping An's insurance, fintech, and healthcare networks create tangible strategic advantage. The firm functions as both a financial investor and a strategic partner, connecting portfolio companies to Ping An's vast distribution ecosystem across China and select global markets.

Pinnacle Ventures is a Burlingame, California-based investment firm founded in 2002 that specializes in providing both venture debt and venture equity financing to high-growth companies across the United States. Led by principals Kenneth R. Pelowski and Robert N. Savoie, the firm operates as investment manager and adviser to a family of venture debt and equity funds — including Pinnacle Ventures Debt Fund III, whose limited partners include The Prudential Insurance Company of America. While sector-agnostic, Pinnacle concentrates its activity in clean technology, healthcare, and information technology, with particular emphasis on internet, mobile, media, enterprise, and software companies. Pinnacle writes venture-debt checks from $500,000 up to $25 million and venture-equity checks up to $15 million, offering founders flexible growth-capital solutions that complement equity rounds without undue dilution. Across 177 investments in 137 unique portfolio companies, the firm has produced 2 unicorns and 98 exits — a strong track record for a venture-debt-led platform. Notable portfolio companies include One Medical, Bonobos, and Kabam. The firm's most recent disclosed investment was a $50 million Series C round in VOOX in January 2025, and its most recent exit was Lotame, acquired by Publicis Groupe in March 2025. Pinnacle's dual debt-plus-equity model is central to its value proposition: by combining venture loans with equity participations, the firm can tailor capital structures to each company's growth trajectory and founder preferences. This flexibility positions Pinnacle as a complement to traditional equity-only VCs and allows founders to preserve dilution while accessing growth runway. The firm's long operating history since 2002 gives it a broad perspective across market cycles.

Pioneer Fund, founded in 2018, is a venture capital firm driven by over 400 Y Combinator alumni, targeting early-stage investments in startups emerging from the Y Combinator accelerator. The fund focuses primarily on seed rounds and is industry-agnostic, backing companies across sectors like AI, fintech, life sciences, and consumer products. Notably, Pioneer Fund has supported the rise of Anthropic, an AI startup that became a unicorn in 2023. Geographically, Pioneer Fund predominantly invests in the US, but has also expanded its portfolio with startups from India, Nigeria, and several other countries. The firm tends to co-invest with other prominent players, often alongside Y Combinator itself, as well as other top-tier VCs. Their strategy revolves around writing early checks and providing more than just capital—leveraging the collective expertise of their vast alumni network to offer founders mentorship, connections, and operational insights. Pioneer Fund typically doesn't lead rounds but is quick to follow other strong investors within the YC ecosystem. The fund is managed by a large team of partners and venture partners based in locations like San Francisco, Toronto, and Vancouver. If you’re a YC startup with a strong product-market fit and a clear path to growth, Pioneer Fund might be a key player in your next funding round, especially if you seek connections within the YC network.

Pioneer Fund, founded in 2017, is a venture capital firm based in San Francisco, CA, and Toronto, Canada. This unique fund is driven by over 400 Y Combinator alumni, focusing on investing in top startups that emerge from the Y Combinator accelerator. With a strong emphasis on early-stage investments, Pioneer Fund supports a diverse range of industries, including consumer products, financial services, AI, life sciences, and education technology. Notable investments by Pioneer Fund include companies like Aspire, C16 Biosciences, Curebase, Dover, and OnDeck, reflecting their broad and impactful portfolio. The fund has made over 600 investments and continues to actively support new ventures, emphasizing their commitment to fostering innovation and growth in the startup ecosystem. Pioneer Fund operates with a flexible and founder-friendly approach, often providing quick investment decisions. They also maintain a global investment perspective, with a presence in countries such as India, Nigeria, Argentina, and Chile. This geographical diversity enables them to back startups with international ambitions and scalability. The team at Pioneer Fund is led by founder Daniel Gross, along with other notable members such as Tim Suzman and Rajiv Bhat. They bring a wealth of experience and connections, leveraging their backgrounds as Y Combinator alumni to provide valuable mentorship and support to portfolio companies.

Pipeline Capital is a seed-stage venture capital firm based in Menlo Park, California. Founded in 2014, the firm focuses on investing in innovative business models within both enterprise and consumer technology sectors. Notable investments include Hippo Insurance and Webflow, which highlight their interest in disruptive companies with significant market potential. Their portfolio showcases a variety of industries, with a particular emphasis on enterprise applications and infrastructure. Recent investments include companies like Haul in the consumer sector and Five Sigma Labs in InsurTech, demonstrating their broad investment scope​. Pipeline Capital's strategy revolves around providing not just capital but also mentorship and extensive support to help startups achieve their full potential. They are highly involved with their portfolio companies, offering guidance and leveraging their networks to drive growth and success. The firm has a history of successful exits, including the acquisition of Spiff by Salesforce and the IPO of Hippo Insurance on the NYSE. This track record underscores their ability to identify and nurture high-potential startups from early stages to successful exits.

Pitango Venture Capital, established in 1993 and based in Herzliya, Israel, is one of the largest and most prominent venture capital firms in Israel, managing over $3 billion across various funds. The firm focuses on investing in early-stage startups through Pitango First, growth-stage companies through Pitango Growth, and health tech innovations through Pitango HealthTech. Pitango has backed a range of notable companies that have become leaders in their respective fields. These include Via Transportation, which has revolutionized urban mobility, Taboola, a significant player in content recommendation and discovery, and Varonis Systems, a cybersecurity company. The firm has also been involved in successful exits, such as the acquisition of Anobit by Apple and the IPO of Radware on NASDAQ. The investment strategy of Pitango emphasizes partnering with visionary entrepreneurs and providing them with the necessary resources and guidance to scale their businesses. The team at Pitango includes experienced professionals like Nechemia (Chemi) Peres and Rami Kalish, who bring a wealth of expertise to the firm’s diverse investment portfolio. Pitango's approach is characterized by a strong commitment to innovation and sustainability, ensuring that the companies they invest in are not only successful but also contribute positively to the broader community. This dedication has positioned Pitango as a key player in both the Israeli and global venture capital ecosystems.

Pitbull Ventures is a Los Angeles-based pre-seed venture capital firm founded in 2021 by Brad Zions, who serves as Founder and Managing General Partner. Zions has been an active early-stage investor for more than 25 years, previously as a partner at Structure Fund and as a prolific individual angel, before institutionalizing his practice under the Pitbull brand. Pitbull closed its $5 million Fund I with a specific thesis: backing AI-enabled industry-vertical SaaS startups during a challenging funding environment for pre-seed companies. The fund's strategy centers on founding teams that leverage artificial intelligence within specific industry verticals and have already demonstrated early product-market fit. Pitbull targets a portfolio of 50-plus companies per fund, with sector interests spanning health tech, enterprise applications, consumer, and business products. Typical check sizes range from $100,000 to $250,000. Across Brad Zions' angel and institutional activity, Pitbull Ventures has made 36 disclosed investments; the Fund I vehicle has actively backed 15 vertical SaaS startups. Notable portfolio companies include Cartwheel (multimedia and design software), OptimHire, LOST iN, Harri, VidMob, and Embrace. Recent exits include Podsights, Jukin Media, and Donut Media. Zions brings a deliberate philosophical stance to the portfolio: he is publicly skeptical of Web3 and crypto theses, preferring AI-first vertical SaaS as the more durable opportunity. This focused conviction allows Pitbull Ventures to move quickly at the pre-seed stage, where founder-market fit and early traction signals matter more than sector diversification. The firm's compact size and Zions' long track record as an angel underpin its ability to act as a genuine first-check partner.

Pitch VC (pitch.vc) is a Melbourne, Australia-based founder-investor matching platform co-founded by Adrian Osman, Campbell Walshe, Jacob Gough, and Kimberly Teo. Rather than operating as a conventional venture capital fund with a fixed investment vehicle, Pitch functions as a curated discovery layer designed to bridge the gap between founders and funders: startups create a structured Pitch profile that is vetted, searchable, and streamlined, while investors use the platform to surface early-stage opportunities without extraneous noise. Pitch positions itself across the pre-seed to Series A spectrum, with particular relevance to software, B2B, and AI-driven companies. The platform hosts portfolio pages for partner accelerators and ecosystems — including Capital Factory, which has 569 companies indexed via pitch.vc — and features startup profiles spanning sectors from aerospace and cybersecurity to fintech and consumer services. Featured startups on the platform have included Portal Aircraft Company (VTOL aerospace), EigenQ (post-quantum cybersecurity), Chateauz (infrastructure intelligence), and Pauv Inc. (talent forecasting). Because Pitch VC operates primarily as a marketplace and syndicated-discovery service, conventional institutional fund metrics such as AUM, committed check sizes, and a formal investment track record are not publicly disclosed. The platform is best categorized as an investor-discovery SaaS service serving the pre-seed-to-seed startup ecosystem rather than a primary capital-deploying fund. Its value lies in reducing friction in the earliest stages of the fundraising process for both founders seeking warm introductions and investors seeking curated deal flow.

Piva Capital is a San Francisco-based venture capital firm, launched in 2019, that targets transformative companies at the intersection of energy, mobility, advanced manufacturing, and new materials. They focus on early to growth-stage startups with breakthrough technologies that address pressing global challenges. Piva backs innovators in fields such as decarbonization, industrial automation, and sustainable production, seeking companies with scalable, cross-industry applications. Some of their notable investments include Boston Metal (decarbonizing steel), Velo3D (revolutionizing additive manufacturing), and Koloma (geologic hydrogen production). Piva’s portfolio is heavily concentrated in North America and Europe, where they partner with visionary entrepreneurs to advance impactful industrial solutions. Piva typically writes large checks, leading rounds and bringing a deep network of industry contacts to help their portfolio companies scale quickly. They are also known for their ESG (Environmental, Social, and Governance) initiatives, embedding sustainability into their investment strategy. The leadership team includes experts like CEO Ricardo Angel and Managing Partner Mark Gudiksen, both based in San Francisco, who bring decades of experience in energy, materials, and industrial sectors​.

Pivotal Ventures, founded by Melinda French Gates in 2015, is a mission-driven investment and incubation company focused on accelerating social progress by addressing systemic barriers, particularly those affecting women and marginalized groups. Unlike traditional VC firms, Pivotal Ventures operates at the intersection of venture capital and philanthropy, deploying a range of funding strategies, including venture investments, grants, and advocacy, to drive impact. The firm primarily targets industries that are crucial for societal progress, such as caregiving, women's health, and technology innovation. Notable investments include companies like CareAcademy, which focuses on training caregivers, and partnerships with funds like Impact America Fund and Rethink Impact, both of which are led by women and emphasize diversity in their investment strategies. Pivotal Ventures is committed to redefining the venture capital landscape by prioritizing diversity and inclusion in both their investment decisions and the teams they support. They are known for investing in early-stage companies and funds that often get overlooked by traditional VCs due to their focus on diverse founders and social impact. Led by Melinda French Gates, with a team including key figures like Erin Harkless Moore, Pivotal Ventures pushes for a more inclusive venture ecosystem, emphasizing that investments with a diversity-first approach are not only socially beneficial but also financially rewarding. The firm’s approach has inspired broader changes in how VC firms evaluate opportunities and support diverse entrepreneurs.

PJC, founded in 2001 and based in Boston, Massachusetts, is an early-stage venture capital firm. PJC focuses on investing in innovative startups across various industries, particularly in AI, consumer technology, health tech, and enterprise software. The firm has made over 129 investments and has achieved several successful exits. Notable investments in PJC's portfolio include Expensify, a leading expense management platform; Nest, a consumer IoT company acquired by Google; and Eden Health, a primary care and insurance navigation service acquired by Centivo. Other significant investments are Neurable, a consumer AI-enabled virtual reality platform, and Openly, a next-generation insurance company. PJC is known for its hands-on approach, providing strategic support and mentorship to help startups scale and achieve market success. The firm emphasizes building long-term relationships with entrepreneurs, supporting them through various stages of growth and development.

Planeteer Capital is a venture capital firm based in New York City that focuses on pre-seed and seed-stage investments in climate tech startups. Founded by Sophie Purdom, a co-founder of Climate Tech VC (CTVC), Planeteer Capital aims to partner with founders who are addressing the challenges of climate change through innovative technologies and solutions. The firm is anchored by an Ivy League endowment and backed by notable investors including Collaborative Fund and former Meta CTO Mike Schroepfer. Planeteer Capital targets sectors such as carbon management, industrial decarbonization, the built environment, climate intelligence and insurance, and sustainable agriculture. The firm’s mission is to empower visionary founders with the necessary capital and network to prove and scale their transformative models. Planeteer Capital distinguishes itself by providing not just financial support, but also strategic guidance and a sophisticated understanding of the climate tech capital stack​​.

Play Ventures is the leading early-stage gaming venture capital firm, founded in 2018 by former gaming entrepreneurs Henric Suuronen and Harri Manninen. The firm operates from headquarters in Singapore, with a second office in Helsinki, Finland, and invests globally. Play's thesis is grounded in a straightforward observation: gaming is the largest form of entertainment at over $200 billion annually — more than twice the combined value of music and film — and gaming mechanics are increasingly powering a new generation of consumer applications beyond traditional games. The firm leads rounds across pre-seed, seed, and Series A in mobile free-to-play games, mobile consumer apps, gaming infrastructure, AI-enhanced tools, and gaming-adjacent SaaS. Play Ventures has raised three funds: Fund I at $30 million (2018), Fund II at $135 million (2021), and Fund III at $140 million (2024) — its largest to date, bringing total AUM to approximately $450 million. As of late 2025, the firm has made 126 investments, delivering 1 unicorn, 1 IPO, and 12 acquisitions. Notable portfolio wins include MPL (Indian gaming unicorn), Huuuge Games, Futureplay Games, Eloelo (live social entertainment with over 90 million users and 150,000 creators), and Reworks (acquired by Playtika for $400 million plus a $200 million earn-out). Recent investments include Cypher Games ($30 million Series A co-led with The Raine Group) and Ray Browser ($6.5 million). Play Ventures takes an active role in each portfolio company, leveraging the founders' own operational backgrounds in gaming to provide substantive guidance on game design, monetization, and distribution strategy. The firm's global footprint across Singapore, Helsinki, and active deal-making in India and the United States gives portfolio companies direct access to the markets and talent pools where gaming growth is concentrated.

Playground Global is an early-stage venture capital firm based in Palo Alto, California, specializing in deep-tech investments. Founded in 2015 by Andy Rubin, Peter Barrett, Matt Hershenson, and Bruce Leak, the firm focuses on transformative technologies that promise to define new industry standards and create entirely new markets. Playground Global's investment strategy targets Seed and Series A companies, with initial investments ranging from $1 million to $20 million. Their portfolio includes companies in next-gen computing, logistics, automation, infrastructure, decarbonization, and engineered biology. The firm recently closed its third fund with $410 million in new capital, bringing its total assets under management to over $1.2 billion. This fund continues Playground's commitment to investing in ambitious founders and groundbreaking technologies. Some notable investments from Fund III include d-Matrix, Ideon Technologies, Amber Bio, Infinimmune, and Atomic AI​. Playground Global supports its portfolio companies not just with capital but also with deep technical and operational expertise. The team, comprising over 40 members, includes many with strong technical backgrounds, ensuring comprehensive support in areas such as engineering, product development, business development, and marketing.

Plexo Capital is a venture capital firm founded in 2018 by Lo Toney, a former partner at Google Ventures (GV). The firm operates on a unique hybrid model, investing both in emerging venture capital funds and directly in early-stage startups, particularly those led by women and people of color. This strategy allows Plexo to tap into a broader and more diverse deal flow, aiming to generate superior returns while increasing diversity within the venture ecosystem. Plexo Capital manages a $42.5 million fund, with investments from prominent backers like Alphabet, Intel Capital, Cisco Investments, and the Ford Foundation. The firm typically invests $500,000 to $5 million in venture funds and $500,000 to $2 million directly in startups. Some of the notable companies in their portfolio include Blavity, PlayVS, and Wrapbook, a payroll management software company that has since become a unicorn. Plexo’s approach is deeply rooted in the belief that diverse perspectives lead to better investment outcomes, particularly at the seed stage where non-traditional networks can provide unique insights. The firm also emphasizes supporting its portfolio companies by leveraging its extensive network of strategic partners and experts in growth, product development, and customer acquisition. Plexo Capital is based in San Francisco but operates globally, with investments spanning across North America, Africa, and Latin America

PLG Ventures is an early-stage venture capital firm based in Santa Monica, California, specializing in providing pre-seed and seed capital to technology-enabled startups. Founded in 2015 by Peter Goldberg, the firm focuses on sectors such as software, SaaS, consumer products, and fintech. Some of their notable investments include AvantStay, an online booking platform for vacation rentals; Hum Capital, a fundraising platform for startups; and Measurabl, which offers SaaS-driven sustainability data collection for buildings. PLG Ventures is known for its hands-on approach, helping founding teams develop leadership skills and company culture while ensuring strong foundations for growth. PLG Ventures aims to support startups by offering a combination of capital, guidance, and strategic resources to help them scale and succeed in competitive markets​.

Plow Ventures, formerly known as Tenzing.vc (Tenzing Capital), is an early-stage venture capital firm founded in 2021 and based in Wichita, Kansas. It is a solo-GP operation led by founder and General Partner Josh Oeding, who before launching the firm spent five years leading NXTUS to grow the regional innovation economy across Kansas and the Midwest, and from 2008 to 2018 held innovation and technology leadership roles at Koch Industries. The firm invests primarily at the pre-seed and seed stage in US-based B2B startups, with a focus on vertical SaaS and fintech, and broader interest in cybersecurity, payments, digital health, analytics, cloud infrastructure, marketplaces and AI, generally as a co-investor. Individual checks are small, roughly $75K to $250K per deal with a sweet spot around $150K, while the firm participates in seed rounds that can range up to about $2M in total size. As of early 2025 the firm had invested in about six companies, with notable holdings including Ovation and WorkTorch, and its most recent disclosed investment was in Mobly as part of a seed round on January 23, 2025. The firm has since rebranded from Tenzing.vc to Plow Ventures, operating under the plowvc.com domain. By writing small first checks into Midwest and US B2B software and fintech founders, Plow Ventures backs companies at the earliest stages and participates alongside larger lead investors as those rounds come together.

Plug and Play Ventures is the venture capital and accelerator arm of Plug and Play Tech Center, one of the world's largest innovation platforms, headquartered in Sunnyvale, California and founded in 2006 by Saeed Amidi. The firm's origins trace to Amidi's family property at 165 University Avenue in Palo Alto, where he and partner Pejman Nozad informally backed building tenants including Google and PayPal. Amidi recycled those returns to open the Plug and Play Tech Center in Sunnyvale — a 150,000-square-foot facility that became the nucleus of a global innovation network now spanning 30-plus locations across five continents, 400-plus corporate partners, and 400-plus VC partners. The firm is technology-agnostic and invests at pre-seed and seed with typical checks of $100,000 to $150,000. Over 19 years, Plug and Play has made more than 2,370 investments — an average of 78 new investments per year in the last decade. The portfolio includes 39 unicorns: among them Dropbox, PayPal, LendingClub, N26, Honey, Guardant Health, Rappi, Hippo, and Zero Hash (which reached unicorn status in 2025). The firm has also produced 24 public listings, including BitGo (NYSE IPO in January 2026 at a $1.92 billion valuation). Sector programs span fintech, health, insurtech, IoT, mobility, sustainability, and agtech. Plug and Play's model pairs early capital with structured acceleration: startups gain access to a curated network of Fortune 500 corporate partners and downstream VCs through 15-plus industry-specific programs running simultaneously. The firm's scale creates a rare compounding advantage — a startup accepted into one program gains credibility, customer introductions, and investor exposure that would otherwise require years to assemble independently.

Plum Alley is a New York-based venture capital firm founded in 2012 by Deborah Jackson and Andrea Moffitt. The firm focuses on investing in early-stage, high-growth technology and healthcare companies, particularly those with at least one female founder from the STEM fields. Their portfolio includes companies like AiFi, which specializes in autonomous checkout technology, and Gameto, a biotechnology company addressing ovarian aging. Plum Alley has a strong emphasis on supporting companies that tackle significant human and environmental challenges using advanced technology. They have invested nearly $80 million across 32 companies through member investors and their Venture Fund I. Their investment strategy includes offering membership opportunities for investors to engage with curated investment opportunities and targeted venture funds focused on specific sectors​​. The firm has made notable exits, including companies like Shine, Node, and Tinkergarten. They also have a robust portfolio of ongoing investments in sectors such as digital health, smart hardware, and automation.

oint72 Ventures is a global venture capital firm founded by Steven A. Cohen in 2016. Based in New York, Seattle, and San Francisco, Point72 Ventures focuses on fintech, artificial intelligence, and enterprise technology sectors. The firm leverages Point72 Ventures is a global venture capital firm founded by Steven A. Cohen in 2016. Based in New York, Seattle, and San Francisco, Point72 Ventures focuses on fintech, artificial intelligence, and enterprise technology sectors. The firm's investment strategy involves thorough research and a deep understanding of industries. Point72 Ventures writes checks from $250k to $50 million, from pre-seed to pre-IPO rounds. They often lead investment rounds and take board seats to support their portfolio companies. Point72 Ventures has a diverse portfolio including Apex, Tektonic AI, and DriveWealth. The team includes experts like Adam Carson, focusing on fintech and crypto, and Pete Casella, a senior advisor with a strong fintech background. Point72 Ventures engages with passionate founders who are deeply knowledgeable about their industries, emphasizing data and thorough analysis in their investment process. They seek companies with clear potential for innovation and growth.

PointGuard Ventures is an early-stage technology investment firm headquartered in Los Altos, California, in the San Francisco Bay Area, founded in 2014 by Krish Panu and T. Peter Thomas — two Silicon Valley venture capital veterans with approximately 35 years of combined venture and operating experience. The firm brands itself after the basketball point guard metaphor: PointGuard acts as the team advisor and coach, while the founder and CEO runs the plays and drives execution. Its thesis centers on backing entrepreneurs who leverage converging technologies to create entirely new markets or solve existing problems dramatically more cost effectively. PointGuard targets Series A and early Series B companies that have achieved product-market validation, a defined sales strategy, and potential IP protection. The firm deploys initial checks of $2 million to $10 million per company, with reserves to reach $10 million or more in select deals. Sector coverage spans cloud computing, SaaS, data analytics, green technology, point-of-care medical devices, semiconductors, networking, and hardware. The firm launched with a $50 million fund and has made 30 disclosed investments. The portfolio has produced 2 IPOs — FormFactor (NASDAQ, June 2003) and Cirrus Logic (NASDAQ) — and 20 acquisitions. The most recent exit was Prevedere, acquired by Board in November 2024. PointGuard keeps a deliberately concentrated portfolio, which allows both Panu and Thomas to be deeply engaged with each management team. The firm provides hands-on coaching across strategy, sales architecture, and operational execution — the 'mentor capital' model that distinguishes PointGuard from funds that take a more passive board-observer approach. This depth of engagement is particularly valued at the Series A stage, when founding teams face their most consequential go-to-market decisions.

Polaris Partners, a venture capital firm established in 1996 and headquartered in Boston, Massachusetts, has a distinguished history of investing in transformative healthcare and biotechnology companies. With over 400 companies funded, more than 100 exits, and 50 IPOs, Polaris Partners has solidified its position as a leading investor in the industry​​. The firm's portfolio is diverse, including notable companies such as Ironwood Pharmaceuticals, JibJab Media, LegalZoom, and Living Proof. Polaris Partners focuses primarily on healthcare, life sciences, and biotechnology sectors, targeting innovative care delivery models, digital health solutions, patient and provider platforms, and data science and analytics​ ​. Polaris Partners operates multiple funds, including the Polaris Growth Fund, which supports the expansion of profitable, founder-owned technology companies, and the Polaris Innovation Fund, aimed at accelerating the commercial and therapeutic potential of early-stage academic research​​. Key team members include Brian Chee, Bryce Youngren, and Alexandra Cantley, who bring extensive expertise and leadership to the firm's investment strategies. Polaris Partners prides itself on being more than just investors—they are builders and connectors with a deep network of syndicate partners, universities, and research institutions​​. For entrepreneurs, Polaris Partners offers robust support, leveraging their decades of experience and comprehensive network to help companies achieve successful outcomes and bring innovative therapies to market.

Polychain Capital, founded in 2016 by Olaf Carlson-Wee, is a prominent venture capital firm based in San Francisco that focuses on investments in cryptocurrency and blockchain technology. The firm has established itself as a leader in the digital asset space, managing a diverse portfolio that includes early-stage ventures and later-stage companies. Polychain Capital has made over 260 investments, with notable exits such as Coinbase, Kik, and Compound. Their investment strategy emphasizes supporting transformative blockchain projects and innovative financial technologies. Recent investments include companies like Particle Network and Riema Labs, highlighting their ongoing commitment to advancing blockchain infrastructure and applications. The firm recently raised $200 million for its fourth crypto venture capital fund, underscoring its significant influence and resources in the industry. Polychain Capital's portfolio is broad, encompassing various sectors within the blockchain ecosystem, from decentralized finance (DeFi) platforms to digital asset management tools. Polychain Capital's approach is characterized by a strong focus on identifying and nurturing high-potential projects that leverage blockchain technology to create scalable and impactful solutions. The firm benefits from a deep network of co-investors, including Coinbase Ventures and Hack VC, which further enhances its ability to support and grow its portfolio companies.

Polytech Ventures is a venture capital firm based in Switzerland, focusing on early-stage investments with a strong international outlook. The firm primarily invests in sectors like fintech, insurtech, healthtech, and proptech. Established in 2015, Polytech Ventures has offices in Lausanne, Switzerland, at the EPFL campus, and in San Francisco, USA, providing a bridge for European startups to access the Silicon Valley ecosystem. Polytech Ventures operates under the umbrella of Polytech Ecosystem Ventures, which combines the strengths of Swiss and European technological innovation with the market access and growth opportunities available in the United States. The firm has a $40 million fund aimed at supporting digital transformation across various industries, including fintech, insurtech, digital health, and retail tech. The fund's strategy involves identifying high-potential startups in Switzerland and Europe and helping them establish a presence in the US to accelerate their growth. Notable portfolio companies include Beekeeper, Saphetor, Inpher, BlueFox, and Weft. Polytech Ventures is committed to fostering innovation by providing both capital and strategic guidance to early-stage companies.

Pontifax Venture Capital is a healthcare-focused venture capital firm based in Herzliya, Israel, founded in 2004. The firm manages approximately $1.2 billion across multiple funds and focuses on identifying and investing in transformative life sciences technologies at all stages of development. Pontifax's portfolio includes around 100 companies that address significant unmet medical needs through groundbreaking innovations​. The firm was co-founded by Eli Hurvitz, a legendary figure in the pharmaceutical industry and former CEO of Teva Pharmaceuticals, alongside Ran Nussbaum and Tomer Kariv. Pontifax takes a hands-on approach with its portfolio companies, providing strategic guidance and leveraging extensive networks to help these companies grow and succeed. Pontifax's investment strategy spans various sectors within the life sciences, including biopharmaceuticals, medical devices, and gene therapy. Notable investments include Kite Pharma, which was acquired by Gilead Sciences, and Eloxx Pharmaceuticals, which focuses on treatments for genetic diseases caused by nonsense mutations.

Pool Global Partners is a venture capital firm that focuses on investing in high-growth technology companies, with an emphasis on sectors such as healthcare, software development, and biotechnology. Founded in 2016 and based in Toronto, Pool Global Partners aims to back innovative startups that leverage deep technology to create transformative solutions. The firm operates with an outcome-driven approach, providing both financial capital and strategic support to help startups scale efficiently. Pool Global Partners’ portfolio includes investments in companies like modl.ai, an AI gaming startup, Prescryptive Health, a healthcare technology company, and Acorn Biolabs, a biotechnology firm. The firm’s investment strategy is centered around early-stage ventures, particularly in seed and Series A rounds, with an average deal size of around $1 million. With a global presence, Pool Global Partners actively collaborates with other venture firms such as Saltagen Ventures and PreSeed Ventures, co-investing in high-potential startups across North America and Europe. Their goal is to support technological innovation that addresses critical challenges, particularly in sectors that are poised for significant growth.

Porsche Ventures is the global corporate venture capital arm of Porsche AG, the Stuttgart-based German luxury sports car manufacturer. Established in 2016, the unit has grown into a systematic startup ecosystem with employees across five international hubs: Luxembourg (legal domicile), Berlin, Palo Alto, Tel Aviv, and Shanghai. The firm is led by Managing Director Ulrich Thiem under the strategic oversight of Lutz Meschke, Deputy Chairman of Porsche AG's Executive Board for Finance and IT. Porsche Ventures operates under a strategy organized around four investment fields: Car and Mobility, Intelligent Enterprise, Sustainability, and Beyond — the last encompassing AI, blockchain, VR/AR, and Web3. The firm maintains an annual investment framework of approximately EUR 150 million and has earmarked up to EUR 250 million for new investments and follow-on tickets. Cumulatively, Porsche has invested approximately EUR 300 million into 52 current portfolio companies, with 72 total disclosed investments, 4 unicorns, 2 IPOs, and 5 acquisitions. Notable portfolio companies include Rimac Automobili (in which Porsche holds a 22% stake via the Bugatti Rimac joint venture), Cresta, Nozomi Networks, TriEye, Anagog, Urgent.ly, WayRay, VAHA, Via, and ZEDEDA (participating in its $72 million Series C). Porsche Ventures functions as both a financial investor and a strategic accelerator: portfolio companies gain access to Porsche's global customer base, engineering expertise, manufacturing know-how, and retail distribution network. The firm's five-hub model ensures deal sourcing proximity to the world's most active technology ecosystems, while its industry focus on mobility and intelligent enterprise keeps the portfolio closely aligned with Porsche AG's own long-term innovation roadmap.

Portal Innovations is a Chicago-based venture development engine that specializes in supporting early-stage life sciences, medtech, and bioinformatics startups. Founded by John Flavin, a seasoned entrepreneur with a strong track record in life sciences, Portal Innovations provides what it calls "Crafted Capital™," which includes seed funding, state-of-the-art lab space, and strategic management support. The firm operates in key U.S. biotech hubs, including Chicago, Atlanta, Boston, and Houston, offering over 80,000 square feet of lab and office space tailored to the needs of its portfolio companies. Portal Innovations has a unique approach that bridges scientific ideation through commercial proof of concept by leveraging strong ties with academic institutions and industry partners. This enables them to identify and nurture promising startups, particularly those emerging from university labs. Portal Innovations' portfolio includes a diverse range of companies such as Cardiosense, which is developing a digital biomarker platform, and ClostraBio, focused on new therapeutics for inflammatory bowel disease and food allergies. The firm’s recent expansion into Houston, in collaboration with the Texas Medical Center, highlights its commitment to growing the U.S. life sciences ecosystem by providing critical resources and support to early-stage companies​.